Clinical trials: Unresectable Hepatocellular Carcinoma (HCC)
HCC - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide.
- Trial name
- NCT07305428
- Testing
- Stereotactic Body Radiation Therapy followed by Immunotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial…
- Trial name
- NCT07845266
- Testing
- GKL-006 Injection, transarterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Unresectable Hepatocellular Carcinoma (HCC)
Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)
- Trial name
- HLP1-1331 (NCT07596134)
- Testing
- Multimodal Thermal Therapy, Targeted and Immune Drugs
- Where
- 7 sites in China
- Volunteers
- 166 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07209813
- Testing
- GKL-006 Injection, TACE
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07713290
- Testing
- GKL-006 Injection, Transarterial chemoembolization (TACE)
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC).
- Trial name
- NCT07547553
- Testing
- Will receive HH-009 injection 20 mg/kg, Q3W, Will receive HH-009 injection 30 mg/kg, Q3W
- Where
- 21 sites in China
- Volunteers
- 30 people
- Sponsor
- Huahui Health
HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma…
- Conditions
- HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
- Trial name
- NCT07535840
- Testing
- Firsekibart + Tislelizumab + Lenvatinib
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital
Unresectable Hepatocellular Carcinoma (HCC)
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07408804
- Testing
- TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- Bangladesh Medical University
Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT07391839
- Testing
- MDN-001 Injection(Yttrium-90 Microsphere Injection)
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Suzhou Mednovo Yi Medical Technology Co., Ltd.
Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma
Using Machine Learning to Identify Responders to TACE or HAIC for uHCC
The goal of this observational study is to learn about the efficacy of Transarterial Chemoembolization (TACE) versus Hepatic Arterial Infusion Chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT07368530
- Testing
- Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
HCC - Hepatocellular Carcinoma, Psychological Distress
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depressed.
- Conditions
- HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
- Trial name
- SOLACE (NCT07141056)
- Testing
- Psychological Stress Status
- Where
- 5 sites in China
- Volunteers
- 700 people
- Sponsor
- Guilin Medical University, China
Unresectable Hepatocellular Carcinoma (HCC)
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05630937
- Testing
- NMS-01940153E
- Where
- 9 sites in United States, Italy and 1 more
- Volunteers
- 31 people
- Sponsor
- Nerviano Medical Sciences
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Unresectable Hepatocellular Carcinoma (HCC)
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as…
- Trial name
- NCT06739317
- Testing
- Radiation, First line therapy, operation
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC…
- Trial name
- SIRtain (NCT05967143)
- Testing
- SIRT
- Where
- 9 sites in France, Spain and 1 more
- Volunteers
- 845 people
- Sponsor
- Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC)
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- NCT02953743
- Testing
- Lenvatinib
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Eisai Co., Ltd.
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
- Trial name
- MEDI-573-1028 (NCT01498952)
- Testing
- MEDI-573 (1 of 3 doses), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC